NRXP
Nrx Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$1.91
+0.23 (+13.69%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.55M | 19.28M | 24.16M |
| Net Income | 2.70M | 1.92M | 2.84M |
| EPS | — | — | — |
| Profit Margin | 12.5% | 10.0% | 11.8% |
| Rev Growth | +2.0% | +3.7% | +21.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 17.94M | 13.97M | 16.93M |
| Total Equity | 26.88M | 27.54M | 30.17M |
| D/E Ratio | 0.67 | 0.51 | 0.56 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.73M | 4.55M | 5.86M |
| Free Cash Flow | 2.93M | 1.59M | 2.98M |